Brief: MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax
26/03/2024 13:49
March 26 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING
ORAL
CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN
PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
* MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT
EXPANSION
COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1
STUDY
* MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE
HEAVILY
PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED
DECREASES IN MCL-1
* MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND
NO
DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION
COHORTS
Source text for Eikon: ID:nBw1vKpxXa
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations